Wechselwirkungen · Xeplion
Xeplion 150 mg and Xeplion 100 mg prolonged release suspension for injection · Abschnitt 4.5 · PDF-Seite 29
HOS-124281 · Präparat HOS-095825
Co-administration of oral paliperidone prolonged release once daily with carbamazepine 200 mg twice daily caused a decrease of approximately 37% in the mean steady-state Cmax and AUC of paliperidone. This decrease is caused, to a substantial degree, by a 35% increase in renal clearance of paliperidone likely as a result of induction of renal P-gp by carbamazepine. A minor decrease in the amount of active substance excreted unchanged in the urine suggests that there was little effect on the CYP metabolism or bioavailability of paliperidone during carbamazepine co-administration. Larger decreases in plasma concentrations of paliperidone could occur with higher doses of carbamazepine. On initiation of carbamazepine, the dose of Xeplion should be re-evaluated and increased if necessary. Conversely, on discontinuation of carbamazepine, the dose of Xeplion should be re-evaluated and decreased if necessary.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): carbamazepine (HOS-085618)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-03T17:43:00Z · SHA-256 2d38bdc767adb9ede103df61263cd780b613b64f4605afd38720f25f2e234f90 · Passage cf3e9d7ec1f754a599551b3b97d4ad6f5fe992fa8f41af657d10958395c8941d · Zeichen 2410–3323 im Abschnitt